Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOST Plus
2023-510566-27-00Phase 2Authorised
- Sponsor
- Centre Léon Bérard
- Start
- Feb 2014
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tiragolumab, durvalumab, nilotinib and olaparib in Nonhematologic neoplasms and cancer (2 arms), sponsored by Centre Léon Bérard. Primary endpoints: 12-week progression-free rate and Progression-free survival. Planned start Feb 2014; status: authorised.
02
Drugs
tiragolumabdurvalumabnilotinibolaparib
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on 2023-510566-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510566-27-00.